Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00521794 · ClinicalTrials.gov registry record

Characteristics of Andersen-Tawil Syndrome

A clinical trial, sponsored by University of Rochester.

Completed
Registry status
28
Enrollment target

NCT00521794 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00521794 has completed, sponsored by University of Rochester.

COMPLETED
Registry status
28 participants
Enrollment target

Study Summary

Andersen-Tawil Syndrome (ATS) is a rare, genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and developmental abnormalities. Disease symptoms can vary, the cause of some ATS cases remains unknown, and no specific treatment has been identified. The purpose of this multi-site study is to better characterize ATS, establish whether symptoms change over time, and determine if symptoms are related to a mutation in the KCNJ2 gene.

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2007-11
Est. Completion 2012-10

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00521794

The ClinicalTrials.gov registry entry for NCT00521794 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00521794 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00521794 about?

NCT00521794 is a clinical study titled "Characteristics of Andersen-Tawil Syndrome". Andersen-Tawil Syndrome (ATS) is a rare, genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and developmental abnormalities. Disease symptoms can vary, the cause of some ATS cases remains unknown, and no specific treatment has been identif...

What is the current status of trial NCT00521794?

This trial is currently completed. The enrollment target is 28 participants. The study started on 2007-11. Estimated completion is 2012-10.

Who is sponsoring clinical trial NCT00521794?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.